Immunocore Ltd, which is developing cancer therapies based on T cell receptors, has appointed Andrew Hotchkiss as its chief commercial officer. Mr Hotchkiss joins the UK company from Eli Lilly & Co where was senior vice president for digital ventures and before that, head of the US company’s international oncology business unit. He holds a degree in biochemistry from University College Cardiff in the UK.
Immunocore announced the appointment on 4 October 2017.
Copyright 2017 Evernow Publishing Ltd